News
-
German digital health company VisionHealth has announced that it will “cooperate on distribution of inhalation platform Kata” with Boehringer Ingelheim in Germany. The Kata app uses artificial intelligence and augmented reality technology in conjunction with… Read more . . .
-
TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding… Read more . . .
-
According to Theravance Biopharma, the company is selling its stake in Theravance Respiratory Company (TRC), which received royalties from sales of GSK’s Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI. The deal with Royalty Pharma… Read more . . .
-
Glenmark Pharmaceuticals and SaNOtize have announced the publication of results from a Phase 3 clinical trial of NONS nitric oxide nasal spray for the treatment of COVID-19 in The Lancet Regional Health Southeast Asia. SaNOtize announced initiation… Read more . . .
-
Pulmatrix said that the first subjects have been dosed in a Phase 1 trial of the company’s PUR3100 dry powder dihydroergotamine (DHE), which is based on Pulmatrix’s iSPERSE particle engineering platform. The company announced in… Read more . . .
-
Israeli startup NurExone Biologic has announced that it will pay Israeli nasal delivery specialist Polyrizon a total of up to $3,350,000 for development of an intranasal formulation of NurExone’s ExoTherapy, exosomes loaded with modified siRNA… Read more . . .
-
Bayer said that its Astepro Allergy azelastine nasal spray is now available over the counter in US retail stores for the treatment of respiratory allergy symptoms in people aged 6 and older. The FDA approved… Read more . . .
-
US-based startup RS BioTherapeutics has announced that a proof of concept study demonstrated that its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) reduced but did not eliminate cytokines when dosed intranasally at 1 mg/kg in a mouse… Read more . . .
-
Intranasal vaccine developer Meissa Vaccines has announced that Martin Moore is stepping down as the company’s CEO and Frank Glavin has joined the company as the new Chief Executive Officer. Moore will stay with Meissa… Read more . . .
-
According to Beyond Air, the FDA has approved the company’s LungFit PH inhaled nitric oxide (iNO) generation and delivery system for the treatment of babies with persistent pulmonary hypertension of the newborn (PPHN). The approval is… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.